Abstract
Among the many clinical practices that use Baduanjin as a treatment for type 2 diabetes patients, it has shown to be effective, but there is still a lack of research on molecular regulation mechanisms. Meta-analysis and transcriptome analysis are used in this study to reveal the evidence and molecular regulation of Baduanjin in diabetes treatment. Twenty-eight randomized controlled trials studies were included after systematic searches of major medical databases. Compared with placebo, Baduanjin significantly improved FBG levels, however heterogeneity was eliminated when average age exceeded 60 years and exercise duration exceeded 12 weeks were matched. The next step was to investigate the molecular mechanism of Baduanjin against diabetes. This was done by selecting diabetics over 60 years of age with type 2 diabetes. Then we detected the levels of long noncoding RNA, circular RNA, and mRNA in the blood of type 2 diabetes patients before and after the intervention of Baduanjin for 12 weeks. Our analysis used sequencing and bioinformatics methods to identify differentially expressed genes, circRNAs, and lncRNAs possibly related to the regulation of diabetes by Baduanjin. From peripheral blood of patients with diabetes before and after Baduanjin intervention, 4244 DE mRNAs, 463 lncRNAs, and 516 circRNAs were determined. Systematic bioinformatics analysis revealed that the DE genes are functionally rich in oxidative phosphorylation and cytokine-cytokine receptor interaction. In addition, the results indicated that the potential ENST00000512668-G0S2 interplay, which has been methodically validated in the lncRNA prediction database, participates in Baduanjin regulation of diabetes by altering oxidative phosphorylation in patients with diabetes. This finding provides molecular targets for improving the use of Baduanjin as adjunctive therapy for diabetes.